| Literature DB >> 36273237 |
Akira Nakazato1,2,3, Mai Mochizuki1, Rie Shibuya-Takahashi1, Haruna Fujimori1, Keitaro Fujii2, Satoshi Saijoh2, Shinkichi Morita2, Tomoko Yamazaki4, Takayuki Imai2, Ikuro Sato5, Kennichi Satoh6, Kazunori Yamaguchi7, Kazuo Sugamura7, Jun Yasuda7, Kazuto Matsuura8, Hideo Shojaku3, Yukinori Asada2, Keiichi Tamai9.
Abstract
CD271 (also referred to as nerve growth factor receptor or p75NTR) is expressed on cancer stem cells in hypopharyngeal cancer (HPC) and regulates cell proliferation. Because elevated expression of CD271 increases cancer malignancy and correlates with poor prognosis, CD271 could be a promising therapeutic target; however, little is known about the induction of CD271 expression and especially its promoter activity. In this study, we screened transcription factors and found that RELA (p65), a subunit of nuclear factor kappaB (NF-κB), is critical for CD271 transcription in cancer cells. Specifically, we found that RELA promoted CD271 transcription in squamous cell carcinoma cell lines but not in normal epithelium and neuroblastoma cell lines. Within the CD271 promoter sequence, region + 957 to + 1138 was important for RELA binding, and cells harboring deletions in proximity to the + 1045 region decreased CD271 expression and sphere-formation activity. Additionally, we found that clinical tissue samples showing elevated CD271 expression were enriched in RELA-binding sites and that HPC tissues showed elevated levels of both CD271 and phosphorylated RELA. These data suggested that RELA increases CD271 expression and that inhibition of RELA binding to the CD271 promoter could be an effective therapeutic target.Entities:
Year: 2022 PMID: 36273237 DOI: 10.1038/s41598-022-22736-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996